Array Biopharma, Inc. (ARRY) Posts Q2 Loss of $0.06, Sales Top Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.19 -3.33%
Revenue Growth %: -18.0%
Financial Fact:
Interest expense: -2.98M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -18.0%
Financial Fact:
Interest expense: -2.98M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $21.76 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI-powered cyber threats light a fire under cybersecurity stocks
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
